tbuckley/cabot-search huggingface dataset:
TCTAP A-054 Prognostic Impact of Coronary CT Angiography-Detected High-Risk Plaques on Patients After Stenting for Integrated Backscatter IVUS-Identified Thin-Cap Fibro Atheroma (TCFA)
Authors: Masaya Ohta, Hideki Kawai, Masato Ishikawa, Hideaki Oota, Takashi Muramatsu, Yukio Ozaki, Hideo Izawa
Journal: Journal of the American College of Cardiology (2025)
TCTAP A-093 Role of Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Naiela Ennaji Almansouri, Ahmed Ibrahim, Ahmed Samir Mujahed, Ahmad S. Ghattas, Mahmoud Sayed Ahmed, Omar M. Ramdan, Ahmed A. Lashin, Suhaina Amir, Ismail A. Ibrahim
Journal: Journal of the American College of Cardiology (2025)
TCTAP A-030 Development and Validation of a Global Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The Taiwan Research Initiative on Coronary Total Occlusion (TRIO) Score
Authors: Cheng-Wei Lien, Khaled Saber Qayed, Chih-Fan Yeh, Hsien-Li Kao, Ching-Chang Huang
Journal: Journal of the American College of Cardiology (2025)
TCTAP A-001 Patients With a Small Annulus in the LANDMARK Trial - Early Outcomes With Three TAVI Valves
Authors: Patrick Serruys, Akihiro Tobe, Niels van Royen, Ignacio Amat-Santos, Martin Hudec, Matjaz Bunc, Alexander Ijsselmuiden, Peep Laanmets, Daniel Unic, Bela Merkely, Renicus Hermanides, Vlasis Ninios, Marcin Protasiewicz, Benno Rensing, Pedro Martin, Fausto Feres, Manuel Almeida, Eric van Belle, Axel Linke, Alfonso Ielasi, Matteo Montorfano, Mark Webster, Konstantinos Toutouzas, Emmanuel Teiger, Francesco Bedogni, Michiel Voskuil, Manuel Pan, Oskar Angreas, Won-Keum Kim, Jurgen Rothe, Ivica Kristic, Vicente Peral, Mohamed Abdel-Wahab, Ashokkumar Thakkar, Udita Chandra, Marie-Claude Morice, Osama Soliman, Yoshinobu Onuma, Andreas Baumbach
Journal: Journal of the American College of Cardiology (2025)
TCTAP A-013 Clinical Outcomes of Patients With ST-Elevation Myocardial Infarction Treated With Drug-Coated Balloons and/or Drug-Eluting Stents
Authors: Nancy Virginia, Kai Soon Liew, Huan Yean Kang, Chai Yih Tan, Kenneth Kay Leong Khoo, Prabahkar Subramaniam, Mohd Khairi Othman, Aditya Fahmi Prianda, Saravanan Krishinan, Kantha Rao Narasamuloo, Chee Tat Liew, Dharmaraj Karthikesan
Journal: Journal of the American College of Cardiology (2025)
TCTAP A-009 Insights and Outcomes of PCI in a Sri Lankan Tertiary Care Center: A Real-World Study
Authors: M.B.Faslur Rahuman, Nimali Fernando, Chathurika Kempitiya, Anushka Peiris, Pasan Abeysenevi, Amanda Nawarathna, Reeni Robert, Pubudu De Silva
Journal: Journal of the American College of Cardiology (2025)
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
Authors: Steffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, Yacine Maringer, Hans-Georg Rammensee, Cecile Gouttefangeas, Sven Fillinger, Tatjana Bilich, Jonas S Heitmann, Sven Nahnsen, Juliane S Walz
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remain challenging. Methods Over 10,000 raw mass spectrometry (MS) files from over 3,000 tissue samples were analyzed, summing to approximately seven terabytes of data. The raw MS data were processed using the standardized and open-source nf-core pipelines MHCquant2 and epitopeprediction, providing a uniform procedure for data handling. A global false discovery rate was applied to minimize false-positive identifications. Results Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/ ), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes &gt;6.6 million HLA class I and &gt;3.4 million HLA class II peptides from over 40 tissue types and cancer entities. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens (TAAs) as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent TAAs matching the immunopeptidome of the individual patient’s tumor and a neoepitope-based vaccine matching the mutational profile of a patient with cancer. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these patients with advanced cancer. Conclusion The PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.
CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma
Authors: Monica M Cho, Longzhen Song, Aicha E Quamine, Fernanda Szewc, Lei Shi, Johnathan D Ebben, David P Turicek, Jillian M Kline, Devin M Burpee, Emily O Lafeber, Madison F Phillips, Amanda S Ceas, Paul D Bates, Matthew H Forsberg, John A Kink, Amy K Erbe, Christian M Capitini
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Allogeneic bone marrow transplant (alloBMT) is curative for hematologic malignancies through the graft-versus-tumor (GVT) effect but has been ineffective for solid tumors like osteosarcoma (OS). OS expresses CD155 which interacts strongly with inhibitory receptors TIGIT and CD96 but also binds to activating receptor DNAM-1 on natural killer (NK) cells. CD155 has never been targeted after alloBMT. Combining adoptively transferred allogeneic NK (alloNK) cells with CD155 blockade after alloBMT may enhance a GVT effect against OS. Methods Murine NK cells were activated and expanded ex vivo with superagonist interleukin (IL)-15/IL-15Rα. AlloNK and syngeneic NK (synNK) cell phenotype, cytotoxicity, cytokine production, and degranulation against CD155-expressing murine OS cell line K7M2 were assessed in vitro. Mice bearing pulmonary OS metastases underwent alloBMT and alloNK cell infusion with anti-CD155 either before or after tumor induction, with select groups receiving anti-DNAM-1 pretreated alloNK cells. Tumor growth, graft-versus-host disease and survival were monitored, and differential gene expression of lung tissue was assessed by RNA microarray. Results AlloNK cells exhibited superior cytotoxicity against CD155-expressing OS compared with synNK cells, and this activity was enhanced by CD155 blockade. CD155 blockade increased alloNK cell degranulation and interferon gamma production through DNAM-1. In vivo, CD155 blockade with alloNK infusion increased survival when treating OS that relapsed after alloBMT. No benefit was seen for treating established OS before alloBMT. Combining CD155 and anti-DNAM-1 pretreated alloNK did not affect survival and tumor control benefits seen with CD155 blockade alone. RNA microarray showed mice treated with alloNK and CD155 blockade had increased expression of cytotoxicity genes and the NKG2D ligand H60a, whereas mice treated with anti-DNAM-1 pretreated alloNK cells resulted in upregulation of NK cell inhibitory receptor genes. Whereas blocking DNAM-1 on alloNK abrogated cytotoxicity, blocking NKG2D had no effect, implying DNAM-1:CD155 engagement drives alloNK activation against OS. Conclusions These results demonstrate the safety and efficacy of infusing alloNK cells with CD155 blockade to mount a GVT effect against OS and show benefits are in part through DNAM-1. Defining the hierarchy of receptors that govern alloNK responses is critical to translating alloNK cell infusions and immune checkpoint inhibition for solid tumors treated with alloBMT.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Authors: Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang, Thomas James Flotte, Eric P Grewal, Robert R McWilliams, Lisa A Kottschade, Evidio Domingo-Musibay, Svetomir N Markovic, Anastasios Dimou, Heather N Montane, Mara A Piltin, Daniel L Price, Samir S Khariwala, Jane Yuet Ching Hui, Courtney L Erskine, Carrie A Strand, David Zahrieh, Haidong Dong, Tina J Hieken
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each. Methods We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets. Results With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence. Conclusions Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients. Trial registration number NCT03554083 .
METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation
Authors: Yonghua Tong, Zhiqiang Chen, Jian Wu, Qiu Huang, Yu He, Haojie Shang, Ding Xia, Ejun Peng, Zhihua Wang, Xiaoyu Liang, Kun Tang
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Bladder cancer (BLCA) is a challenging malignancy with a poor prognosis, particularly in muscle-invasive cases. Despite recent advancements in immunotherapy, response rates remain suboptimal. This study investigates the role of METTL3, an m6A RNA methylation “writer,” in regulating the immune microenvironment of BLCA. Methods Through bioinformatics analysis, we identified METTL3 as being associated with the formation of an immunosuppressive microenvironment in BLCA and poor response to immunotherapy. Subsequently, we silenced METTL3 expression in BLCA cells using short hairpin RNA (shRNA) or inhibited its function with STM2457. The effectiveness of these interventions in remodeling the BLCA tumor microenvironment (TME) was confirmed through animal experiments and flow cytometry. Mechanistically, RNA sequencing and methylated RNA immunoprecipitation (MeRIP) sequencing revealed the molecular pathways by which METTL3 regulates the TME. This was further validated using in vitro cell co-culture, immunoprecipitation, ELISA, and RNA degradation assays. The synergistic effect of METTL3 with anti-Programmed Cell Death Protein 1 (PD-1) treatment in BLCA was confirmed in both orthotopic and ectopic BLCA animal models. Results METTL3 was found to increase CXCL5 levels and suppress CCL5 expression in an m6A-dependent manner, leading to increased recruitment of myeloid-derived suppressor cells (MDSCs) and reduced infiltration of CD8+T cells. Silencing METTL3 or inhibiting its function restored immune cell balance and significantly enhanced the efficacy of anti-PD-1 therapy. Clinically, METTL3 overexpression correlated with poor complete response rate to immune checkpoint inhibitors (ICIs) therapy, associated with an immunosuppressive microenvironment characterized by elevated MDSC levels and reduced CD8+T cell infiltration. Conclusions These findings highlight METTL3 as a key regulator of the immune microenvironment in BLCA and a promising therapeutic target to improve immunotherapy outcomes. Targeting METTL3 could potentially enhance the efficacy of ICIs in patients with BLCA.
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancer
Authors: Zhi-Yu Xia, Jia-Cheng Xiang, Jin-Zhou Xu, Jian-Xuan Sun, Shaogang Wang, Qi-Dong Xia
Journal: Journal for ImmunoTherapy of Cancer (2025)

Irreversible electroporation (IRE), a non-thermal focal therapy, employs high-frequency electrical pulses to create tumor cell membrane nanopores, inducing immunogenic cell death. By triggering damage-associated molecular patterns, IRE activates dendritic cells (DCs) to prime systemic cytotoxic T lymphocyte (CTL) responses. However, IRE-activated CTLs predominantly accumulate in perivascular regions, limiting their infiltration into the tumor parenchyma. Oncolytic viruses (OVs) complement IRE by converting the “primed” but spatially restricted CTL response into a robust, intratumoral immune attack. OVs secrete pro-inflammatory chemokines to chemoattract CTLs into the tumor core, while the non-thermal nature of IRE preserves antigen stability and vascular integrity, collectively sustaining DC activation and CTL infiltration. Moreover, intraoperative ultrasound-guided IRE not only establishes physical channels for precise OVs delivery but also enhances tumor cell susceptibility to OVs by disrupting membrane integrity. By bridging focal ablation with adaptive immunity, the synergistic effect—IRE for systemic CTL priming and OVs for localized immune amplification—transforms residual tumors into immunogenic niches, counteracting post-IRE recurrence through durable CTL-mediated clearance. The strategy leverages IRE’s functional preservation and OVs’ targeted lytic activity to synergistically enhance therapeutic efficacy while minimizing invasiveness.
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients
Authors: Qingjian Xie, Kezheng Li, Yinuo Chen, Yaojia Li, Wenhua Jiang, Wen Cao, Huan Yu, Dongsheng Fan, Binbin Deng
Journal: Translational Neurodegeneration (2025)

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that remains incurable. Although the etiologies of ALS are diverse and the precise pathogenic mechanisms are not fully understood, approximately 20% of ALS cases are caused by genetic factors. Therefore, advancing targeted gene therapies holds significant promise, at least for the 20% of ALS patients with genetic etiologies. In this review, we summarize the main strategies and techniques of current ALS gene therapies based on ALS risk genes, and review recent findings from animal studies and clinical trials. Additionally, we highlight ALS-related genes with well-understood pathogenic mechanisms and the potential of numerous emerging gene-targeted therapeutic approaches for ALS.
TCTAP C-208 In Doubt of High-Risk Noncardiac Surgery Following Percutaneous Coronary Intervention (PCI) and Transcatheter Aortic Valve Replacement (TAVR): When Is the Best Time?
Authors: Apichat Jansillapakorn, Kittipong Youpaniad, Anuruck Jeamanukoolkit, Wasant Soonfuang, Sukhum Tachasakunjaroen, Sakolwat Montrivade
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-191 Precision in Ostial LAD CTO Stenting: How IVUS Technology Shapes the Future of PCI
Authors: Faiz Mashood, David Yong, Ong Siew Hoon, Goay Swee En, Teoh Chee Kiang, Rafidah Abu Bakar, Amin Ariff Nuruddin
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-203 Navigating Complexity: From Collapse to Recovery With Successful TAVI, PCI and ECMO in a High-Risk Patient
Authors: Tsz Ho Chan, Hei Tung Chan, Ling Na Wong, Chak Yu Kent So, Ka Ho Kevin Kam, Ho Lam, Ka Lung Chui, Eugene B. Wu, Yat Sun Joseph Chan
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-171 RSVG Angioplasty for Distal De-Novo Lesion Using Drug Eluting Stent and Proximal ISR Using Drug Coated Balloon in an Elderly Patient With NSTEMI, Post CABG Status With Mild LV Dysfunction and CKD
Authors: Basabendra Choudhury, Jayanta Saha
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-163 Rescue Stenting of Acute Severe Iatrogenic Flow-Limiting Dissection of Left Main Coronary Artery During Percutaneous Coronary Intervention of Left Anterior Descending Artery
Authors: Quek Ao Xiang, Cheng Jin Kiang, Lau Waye Young, Sim Jian Hao, Ng Wee Pang, Wong Wen Sheng, Kim Heng Shee
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-195 A Challenging Case Report of Coronary Embolism Originating From an Aortomitral Intervalvular Fibrosa Pseudoaneurysm in a Patient With Infective Endocarditis, Status Post Aortic Valve Replacement and Mitral Valve Repair
Authors: Kittichok Jonggonsuwan, Wittawat Wattanasiriporn
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-155 Twists and Turns: Unraveling Spiral Coronary Dissection and Catheter Kinking in Diagnostic Angiography
Authors: Verry Gunawan Sohan, Amir Aziz Alkatiri, Doni Firman, Arwin Saleh Mangkuanom, Nanda Iryuza
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-202 Sudden Hemodynamic Collapse Due to Left Ventricular Outflow Tract Obstruction Requiring Emergent Septal Ablation After Transcatheter Aortic Valve Replacement
Authors: Ryo Arita, Kentaro Hayashida, Tomonari Moriizumi, Juri Iwata, Akiyoshi Kajino, Shingo Sakata, Toshinobu Ryuzaki, Hikaru Tsuruta, Hideyuki Shimizu, Masaki Ieda
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-174 Empowering High-Risk Revascularization: Impella-Assisted Approach for Ostial Left Main Lesion and Left Anterior Descending Artery Chronic Total Occlusion in Severe Left Ventricular Dysfunction
Authors: Yi-Hsin Hung, Chih-Fan Yeh, Yi-Lwun Ho, Hsien-Li Ko
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-158 Distal Coronary Artery Perforation Management, Case Report
Authors: Ahmad Bakhtiar Md Radzi, Ahmad Firdaus Zakaria, Muhammad Hanis Muhmad Hamidi, Huzairi Sani, Khairul Shafiq Ibrahim, Raja Ezman Faridz Raja Shariff, Sazzli Shahlan Kasim, Abdul Wahab Undok
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-218 Mitral Intentional Neo-Skirt Left Ventricular Outflow Tract Optimization via Antegrade Upscaling Balloon-Facilitated Leaflet Razing (MINOTAUR) for Valve-in-Valve Transcatheter Mitral Valve Replacement - A Case Series of a Novel Technique to Prevent LVOT Obstruction
Authors: Christina Mew, Ganeev Malhotra, Christopher Cole, Arun Dahiya, Adrian Chong, Danielle Harrop, Samual Hayman, Yash Singbal, Jordan Ross, Stephen Cox, David Trappett, Gemma Duncan, Kellee Korver, Anthony Camuglia
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-215 Advanced Transeptal Optimization for Mitral Transcatheter Edge-to-Edge Repair (M-TEER) in Patients With Post Atrial Septal Defect Closure Device: Case Report
Authors: Varistha Phetcharakupt, Krissada Meemook, Tawai Ngernsritrakul, Thinnakrit Sasiprapha, Surakiat Leelasithorn
Journal: Journal of the American College of Cardiology (2025)
Progranulin deficiency in the brain: the interplay between neuronal and non-neuronal cells
Authors: Katarzyna Gaweda-Walerych, Vanessa Aragona, Simona Lodato, Emilia J Sitek, Ewa Narożańska, Emanuele Buratti
Journal: Translational Neurodegeneration (2025)

Abstract Heterozygous mutations in GRN gene lead to insufficient levels of the progranulin (PGRN) protein, resulting in frontotemporal dementia (FTD) with TAR DNA-binding protein 43 (TDP-43) inclusions, classified pathologically as frontotemporal lobar degeneration (FTLD-TDP). Homozygous GRN mutations are exceedingly rare and cause neuronal ceroid lipofuscinosis 11, a lysosomal storage disease with onset in young adulthood, or an FTD syndrome with late-onset manifestations. In this review, we highlight the broad spectrum of clinical phenotypes associated with PGRN deficiency, including primary progressive aphasia and behavioral variant of frontotemporal dementia. We explore these phenotypes alongside relevant rodent and in vitro human models, ranging from the induced pluripotent stem cell-derived neural progenitors, neurons, microglia, and astrocytes to genetically engineered heterotypic organoids containing both neurons and astrocytes. We summarize advantages and limitations of these models in recapitulating the main FTLD- GRN hallmarks, highlighting the role of non-cell-autonomous mechanisms in the formation of TDP-43 pathology, neuroinflammation, and neurodegeneration. Data obtained from patients’ brain tissues and biofluids, in parallel with single-cell transcriptomics, demonstrate the complexity of interactions among the highly heterogeneous cellular clusters present in the brain, including neurons, astrocytes, microglia, oligodendroglia, endothelial cells, and pericytes. Emerging evidence has revealed that PGRN deficiency is associated with cell cluster-specific, often conserved, genetic and molecular phenotypes in the central nervous system. In this review, we focus on how these distinct cellular populations and their dysfunctional crosstalk contribute to neurodegeneration and neuroinflammation in FTD- GRN . Specifically, we characterize the phenotypes of lipid droplet-accumulating microglia and alterations of myelin lipid content resulting from lysosomal dysfunction caused by PGRN deficiency. Additionally, we consider how the deregulation of glia-neuron communication affects the exchange of organelles such as mitochondria, and the removal of excess toxic products such as protein aggregates, in PGRN-related neurodegeneration.
TCTAP A-049 A Prospective Observational Study of Diagnostic Accuracy and Feasibility of Quantitative Flow Ratio When Compared to Fractional Flow Reserve
Authors: Joseph O’Brien, Kelly Easey, Eleanor Redwood, Thomas Ford, Jessica Marathe, Peter Psaltis, Jayant Ravindran, Rajan Rehan, Andy Yong, Derek Chew, Adam Brown, Dennis Wong
Journal: Journal of the American College of Cardiology (2025)
TCTAP C-220 A Case Report of Device Embolisation: Retrieval of Atrial Septal Occluder With Endoscopic Biopsy Forceps
Authors: Chaiyih Tan, Kaisoon Liew, Huan Yean Kang, Kenneth Khoo, Nancy Virginia, Mohd Khairi Othman, Prabahkar Subramaniam, Dharmaraj Karthikesan, Saravanan Krishinan, Abdul Rahim Wong, Kantha Rao Narasamuloo
Journal: Journal of the American College of Cardiology (2025)